Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
24/7 Wall St. on MSN3h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Hosted on MSN2h
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...
To approve the generic version of Mounjaro or Zepbound, the FDA will need clear evidence that tirzepatide works as well as the branded medication. Zepbound, which contains the active ingredient ...
Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to inventory issues in the third quarter. This led the shares of the company to ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback